Endometriosis: alternative methods of medical treatment

Leticia Muñoz-Hernando¹
Jose L Muñoz-Gonzalez¹
Laura Marqueta-Marques¹
Carmen Alvarez-Conde¹
Álvaro Tejerizo-García¹
Gregorio Lopez-Gonzalez¹
Emilia Villegas-Muñoz²
Angel Martin-Jimenez³
Jesús S Jiménez-López¹

¹Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Universitario 12 de Octubre, Madrid, Spain; ²Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Carlos Haya, Malaga, Spain; ³Endometriosis Unit, Service of Obstetrics and Gynecology, Hospital Son Llatzer, Palma de Mallorca, Spain

Abstract: Endometriosis is an inflammatory estrogen-dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The main purpose of endometriosis management is alleviating pain associated to the disease. This can be achieved surgically or medically, although in most women a combination of both treatments is required. Long-term medical treatment is usually needed in most women. Unfortunately, in most cases, pain symptoms recur between 6 months and 12 months once treatment is stopped. The authors conducted a literature search for English original articles, related to new medical treatments of endometriosis in humans, including articles published in PubMed, Medline, and the Cochrane Library. Keywords included “endometriosis” matched with “medical treatment”, “new treatment”, “GnRH antagonists”, “Aromatase inhibitors”, “selective progesterone receptor modulators”, “anti-TNF α”, and “antiangiogenic factors”. Hormonal treatments currently available are effective in the relief of pain associated to endometriosis. Among new hormonal drugs, association to aromatase inhibitors could be effective in the treatment of women who do not respond to conventional therapies. GnRH antagonists are expected to be as effective as GnRH agonists, but with easier administration (oral). There is a need to find effective treatments that do not block the ovarian function. For this purpose, antiangiogenic factors could be important components of endometriosis therapy in the future. Upcoming researches and controlled clinical trials should focus on these drugs.

Keywords: pharmacological treatment options, aromatase inhibitors, GnRH antagonists, selective progesterone receptor modulators, anti-TNF-α, endometrial tissue, antiangiogenic factors, hormonal treatments

Introduction
Endometriosis is an inflammatory estrogen-dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. It affects between 6% and 10% of women in reproductive age and causes a broad spectrum of pain symptoms ranging from no symptoms to severe dysmenorrhea, dyspareunia, dyschezia, chronic pelvic pain, and infertility.

The main purpose of endometriosis management is alleviating pain associated to the disease. This can be achieved surgically or medically, although in most women a combination of both is required. Long-term medical treatment is needed in most women; unfortunately in most women, pain symptoms recur between 6 months and 12 months once treatment is stopped.

Current medical treatments are based on two mechanisms of action: anti-inflammatory and hormonal. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used commonly in women with dysmenorrhea, although there is not enough evidence to admit that they are effective in the treatment of endometriosis related pain, and there is lack of evidence to recommend one NSAID among the others.

Hormonally active drugs act by blocking the ovarian function and creating a more stable hormonal environment. Hormonal drugs currently used for the
treatment of pain associated to endometriosis are hormonal contraceptives, progestogens and anti-progestogens, gonadotropin releasing hormone (GnRH) agonists and antagonists, and aromatase inhibitors.³

Hormonal contraceptives reduce pain associated to endometriosis, by oral, transdermal, or vaginal administration.⁶–⁸ Progestogens (medroxyprogesterone acetate, oral or depot, dienogest, cyproterone acetate, norethisterone acetate, danazol, levonorgestrel intrauterine device) and anti-progestogens (gestrinone) are also recommended to reduce endometriosis-associated pain.⁵⁻¹¹ GnRH agonists, with and without add-back therapy, are effective in the relief of endometriosis-associated pain, but can be associated with severe side effects.¹² There is insufficient evidence to recommend one among the others, as all hormonal drugs have shown efficacy in the treatment of pain associated to endometriosis. Clinical decision should take into consideration side effects, patient preferences, efficacy, costs, and availability.⁵

All the drugs with proven efficacy in the treatment of pain associated to endometriosis are hormonal drugs and have a contraceptive action. Endometriosis mainly affects women in their reproductive age; hence, these treatments can be inconvenient in the case of gestational desire. There is a need for new medications, effective in the treatment of pain, with an acceptable side effects profile, suitable for long-term use, with no contraceptive effect, and safe to use in the early pregnancy.

In this paper, we present a review of current evidence in the efficacy of newer drugs used for the treatment of endometriosis, such as aromatase inhibitors, GnRH antagonists, and selective progesterone receptor modulators (SPRMs), as well as other new compounds that are under study and still not in clinical use. A brief summary of the studies discussed is tabulated in Table 1.

**Materials and methods**

The authors conducted a literature search for English original articles, related to new medical treatments of endometriosis in humans, including articles published in PubMed, Medline, and the Cochrane Library. Selection criteria included randomized clinical trials (RCTs), observational trials, open-label nonrandomized trials, and case reports related to medical treatments for endometriosis. The Cochrane Library was searched for reviews.

Keywords included “endometriosis”, matched with “medical treatment”, “new treatment”, “GnRH antagonists”, “Aromatase inhibitors”, “selective progesterone receptor modulators”, “anti-TNF α”, and “antiangiogenic factors”.

**Results**

**GnRH antagonists**

The main mechanism of action of GnRH antagonists is competitive receptor occupancy of GnRH receptors; but, unlike agonists, they do not stimulate the gonadotropin release. Therefore, an immediate and reversible suppression of gonadotropin secretion is achieved.¹³ For these reasons, using a GnRH antagonist presumably should be as effective as using a GnRH agonist in the management of endometriosis.¹³ The use of injectable GnRH antagonists (cetrorelix, ganirelix) is currently approved in the context of assisted reproductive technology.¹³

Elagolix is an oral short-acting GnRH antagonist that, unlike injectable GnRH analogs, produces a dose-dependent suppression of pituitary and ovarian hormones in women. That is, elagolix produces partial ovarian suppression at lower doses and full suppression at higher doses.¹⁴

In a randomized, double-blind, placebo-controlled, Phase II study,¹⁴ elagolix treatment significantly improved dysmenorrhea and dyspareunia during the first 12 weeks of treatment. Elagolix showed an acceptable safety and tolerability profile in this study. Treatment-related adverse events were generally mild to moderate in severity and were consistent with the drug’s mechanism of action. The most common ones (in elagolix treatment groups compared with placebo) were headache, nausea, and anxiety. Overall, the median number of hot flashes per day was slightly larger in the elagolix treatment groups. Minimal bone mineral density (BMD) changes were observed with elagolix treatment over the 24 weeks of treatment, but this reduction was lower than the changes observed after 3 months of treatment with the GnRH agonist leuproline acetate.¹⁴

Elagolix is a potential new strategy for achieving partial estrogen suppression in women with endometriosis-related pain, with an acceptable safety profile. However, additional, more robust studies are warranted, and presently there is no strong evidence on the efficacy of GnRH antagonists for endometriosis-associated pain.⁵

**Aromatase inhibitors**

Aromatase is a key enzyme in synthesizing estrogens from androgens, being involved in the conversion of androstenedione and testosterone to estrone and estradiol, respectively.¹⁵

Several studies suggest that aromatase is inappropriately expressed in the eutopic endometrium and ectopic endometrial implants in women with endometriosis as well as in several types of malignant tumors.¹⁶ The expression in
**Table 1** Studies discussed in this publication

<table>
<thead>
<tr>
<th>Drug</th>
<th>Study</th>
<th>Treatment</th>
<th>Main results</th>
<th>Side effects</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GnRH antagonists</strong></td>
<td>Diamond et al&lt;sup&gt;14&lt;/sup&gt;</td>
<td>RCT elagolix 150 mg or 250 mg/day or placebo during 3 months</td>
<td>Elagolix improved dysmenorrhea and dyspareunia</td>
<td>Headache, nausea, anxiety, hot flashes</td>
<td>Phase III RCT</td>
</tr>
<tr>
<td><strong>Aromatase inhibitors</strong></td>
<td>Soysal et al&lt;sup&gt;18&lt;/sup&gt;</td>
<td>RCT anastrozole 1 mg/day with goserelin 3, 6 mg/4 weeks or goserelin alone for 6 months</td>
<td>Longer pain-free interval and lower recurrence rate with combination</td>
<td>Loss of BMD with combination, but not osteoporosis or osteopenia</td>
<td>Use of aromatase inhibitors associated to another hormonal treatment (oral contraceptive pills, progestogens or GnRH analog) recommended only in women in whom all surgical and medical treatments have failed</td>
</tr>
<tr>
<td>Alborzi et al&lt;sup&gt;19&lt;/sup&gt;</td>
<td>RCT letrozole 2, 5 mg/day or triptorelin 3, 75 mg/4 weeks or case control for 2 months</td>
<td>No differences in pregnancy rate and endometriosis recurrence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roghaei et al&lt;sup&gt;20&lt;/sup&gt;</td>
<td>RCT letrozole 2, 5 mg/day or danazol 600 mg/day or placebo for 6 months</td>
<td>Reduction in pain scores in treatment groups</td>
<td>Not reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aromatase inhibitors</strong></td>
<td>Ailawadi et al&lt;sup&gt;21&lt;/sup&gt;</td>
<td>Open-label nonrandomized letrozole 2, 5 mg/day and norethindrone acetate 2, 5 mg/day for 6 months</td>
<td>Reduction in laparoscopically visible endometriotic lesions and pain scores</td>
<td>No changes in BMD</td>
<td></td>
</tr>
<tr>
<td>Remorgida et al&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Open-label nonrandomized letrozole 2, 5 mg/day and norethindrone acetate 2, 5 mg/day for 6 months</td>
<td>Reduced pain symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrero et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Open-label nonrandomized letrozole 2, 5 mg/day and norethindrone acetate 2, 5 mg/day or norethindrone acetate alone for 6 months</td>
<td>Reduced pelvic pain and dyspareunia</td>
<td>No changes in BMD</td>
<td>More frequent in letrozole group (bleeding, joint pain, myalgia, weight gain)</td>
<td></td>
</tr>
<tr>
<td>Ferrero et al&lt;sup&gt;24&lt;/sup&gt;</td>
<td>Open-label nonrandomized letrozole 2, 5 mg/day and norethindrone acetate 2, 5 mg/day for 6 months</td>
<td>Pain improvement, reduction in gastrointestinal symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aromatase inhibitors</strong></td>
<td>Amsterdam et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Open-label nonrandomized anastrozole 1 mg/day and ethinylestradiol 20 μg/day and levonorgestrel 0, 1 mg/day for 6 months</td>
<td>Reduction in pain scores</td>
<td>Headache, hot flashes, mood changes, muscle aches, and breakthrough bleeding</td>
<td></td>
</tr>
<tr>
<td>Remorgida et al&lt;sup&gt;26&lt;/sup&gt;</td>
<td>Open-label nonrandomized letrozole 2, 5 mg/day and desogestrel 75 μg/day for 6 months</td>
<td>Improvement in dysmenorrhea and dyspareunia</td>
<td>No changes in BMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hefler et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Anastrozole vaginal 0.25 mg/day for 6 months</td>
<td>Improvement in dysmenorrhea</td>
<td>Ovarian cysts with combination</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Drug</th>
<th>Study</th>
<th>Treatment</th>
<th>Main results</th>
<th>Side effects</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPRMs</td>
<td>Kettel et al14,35</td>
<td>Open clinical trial, mifepristone 50 mg/day for 6 months</td>
<td>Improvement in pelvic pain</td>
<td>Not significant</td>
<td>Need for more RCT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Open-label study with ulipristal under recruitment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RCT telapristone under recruitment (Phase II)</td>
</tr>
<tr>
<td></td>
<td>Chwalisz et al36</td>
<td>RCT asoprisnil 5, 10 or 25 mg/day or placebo for 3 months</td>
<td>Reduced nonmenstrual pelvic pain and dysmenorrhea</td>
<td>Mild and self-limiting</td>
<td></td>
</tr>
<tr>
<td>Anti-TNF-α</td>
<td>Koninckx et al60</td>
<td>RCT infliximab 5 mg/kg or placebo 3 months prior to surgery</td>
<td>No differences in pain scores</td>
<td>Myalgia, mild infusion reaction, acute tonsillitis, leukemia</td>
<td>No important benefit effect</td>
</tr>
<tr>
<td>Antiangiogenic factors</td>
<td>Machado et al63</td>
<td>RCT rofecoxib 25 mg/day or placebo for 6 months</td>
<td>Improvement in pelvic pain and dysmenorrhea</td>
<td>Not significant (not reported)</td>
<td>Rofecoxib has been withdrawal from the market (severe cardiovascular effects in long-term users)</td>
</tr>
<tr>
<td>Cyclooxygenase 2 inhibitors</td>
<td>Kamencic and Thiel70</td>
<td>RCT pentoxifyline 800 mg/day or control group after surgery for 3 months</td>
<td>Improvement in pain at 2 and 3 months after surgery</td>
<td>Not reported</td>
<td>No current evidence for using pentoxifyline</td>
</tr>
<tr>
<td></td>
<td>Alborzi et al71</td>
<td>RCT pentoxifyline 800 mg/day or placebo after surgery for 6 months</td>
<td>No differences in pregnancy rates and recurrence of symptoms</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Balasch et al72</td>
<td>RCT pentoxifyline 800 mg/day or placebo for 12 months</td>
<td>No difference in pregnancy rates</td>
<td>Not reported</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Creus et al73</td>
<td>RCT pentoxifyline 800 mg/day or placebo for 6 months</td>
<td>No difference in pregnancy rates</td>
<td>Not reported</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** RCT, randomized clinical trial; BMD, bone mineral density; GnRH, gonadotropin releasing hormone; SPRMs, selective progesterone receptor modulators; TNF, tumor necrosis factor.
endometriotic tissue is still subject to some debate since the presence of aromatase by these tissues has not been confirmed by other studies.17

Only three RCTs are reported in literature18–20 using aromatase inhibitors in the treatment of endometriosis. The first of these studies evaluated the efficacy of using either a combination of anastrozole and goserel in 6 months or goserel alone for 6 months after conservative surgery for severe endometriosis.18 Treatment with anastrozole and goserel during 6 months following surgery for severe endometriosis demonstrated longer pain-free intervals and lower symptom recurrence rates than treatment with goserel alone.

Another RCT evaluated the role of letrozole with triptorelin versus case control on the pregnancy rate and the recurrence of symptoms and signs in patients with endometriosis.19 After treatment of 144 infertile women in their reproductive age by laparoscopy, they were divided into three groups: patients from group 1 who received letrozole for 2 months, patients from group 2 who were prescribed triptorelin for 2 months, and patients from group 3 remained as the control group. The results did not show significant differences among the three groups in pregnancy rates and endometriosis recurrence.

The third RCT published compared the impact of letrozole, danazol, and a placebo on pain scores after laparoscopic management of endometriosis.20 Mean pain scores decreased in all groups but returned to the initial levels more quickly in the placebo group when compared to the treatment group. No analysis of BMD or recurrence was carried out after the 6-month treatment period.

An open-label nonrandomized study used letrozole plus norethindrone acetate for 6 months before a second look laparoscopy, resulting in a reduction in macroscopically visible endometriosis and a relief of pain.21

Three prospective, open-label, non-randomized studies used a combination of letrozole and norethindrone acetate daily for 6 months to treat premenopausal patients with endometriosis-related pain, who were unresponsive to previous treatments such as surgery and/or GnRH agonist therapy or showed disease recurrence.22–24 The combination treatment was more effective in reducing pain, but symptoms recurred 3 months after finishing the treatment. Letrozole caused more severe side effects.

Two open-label, non-randomized studies evaluated the efficacy of aromatase inhibitors combined with oral contraceptives in premenopausal patients with endometriosis and pelvic pain unresponsive to multiple medical and surgical treatments.25,26 These treatments induced a relief of pain, but the combination of letrozole plus desogestrel induced ovarian cysts.26

In another study without control group, anastrozole was administered invravaginally to ten patients with rectovaginal endometriosis.27 It did not show any improvement in chronic pelvic pain.

In summary, side effects most commonly associated to the treatment with aromatase inhibitors are headaches, hot flashes, mood changes, muscle aches, and breakthrough bleeding. Estradiol levels were significantly suppressed with the treatment. Significant loss of BMD was noted in the treatment with anastrozole plus goserel,18 but no women fell into the category of osteopenia or osteoporosis. In the other studies, no significant change in BMD was reported.

The studies published do not show a clear evidence of the effectiveness of aromatase inhibitors for the treatment of pain related to endometriosis. Major limitations to their use are recurrences after finishing treatment, severe side effects, and cost.28 The European Society of Human Reproduction and Embryology (ESHRE) in their latest guideline7 recommends the use of aromatase inhibitors associated to another hormonal treatment (oral contraceptive pills, progestogens, or GnRH analogs) only in women in whom all surgical and medical treatments have failed.

Selective progesterone receptor modulators

SPRMs are defined as a new class of progesterone receptor ligands, which exhibit both progesterone agonistic and antagonistic activities.29 In the absence of progesterone, the SPRMs act like weak progestins. In the presence of progesterone, they may also show weak antiprogestagenic properties in some tissues, particularly in the endometrium. This property justifies their use in the treatment of myomas and endometriosis. Only two drugs are currently approved for gynecologic use. Mifepristone is approved for the termination of pregnancy, cervical dilation, medical termination of pregnancy during the second trimester, and fetal death in utero.30,31 Ulipristal acetate has been approved in Europe and the United States as an emergency contraceptive, and recently the European Commission has also approved ulipristal acetate for the preoperative treatment of uterine fibroids.32,33

Only two small open clinical trials have been published using mifepristone for the treatment of endometriosis. Mifepristone at 50 mg daily dose has been shown to improve pain and cause regression of endometriosis implants,34 but at a
lower dose is unable to control the growth of endometriosis lesions.\textsuperscript{35}

A randomized placebo-controlled clinical trial using asoprisnil in the treatment of endometriosis-associated pain has been reported in an abstract form.\textsuperscript{36} Subjects with a laparoscopic diagnosis of endometriosis, exhibiting moderate or severe pain at baseline were treated with asoprisnil (5 mg, 10 mg, and 25 mg) or placebo for 12 weeks. All three asoprisnil doses significantly reduced the average daily combined nonmenstrual pelvic pain/dysmenorrhea scores compared to placebo, and had a favorable safety and tolerability profile during the 3-month treatment period. There were no laboratories or clinical signs of estrogen deprivation.

Common side effects of SPRMs are headache, abdominal pain, and tenderness. They induce endometrial changes known as progesterone receptor modulator-associated endometrial changes (PAECs). The levels of estrogens are maintained, and BMD is not affected.

More number of RCTs must be developed to assess the potential benefit of SPRMs in the management of pain associated to endometriosis, and the long-term security and endometrial changes associated must be clarified. SPRMs seem to be a promising medical treatment(s) in endometriosis.

Anti-tumor necrosis factor-\(\alpha\)

A feature of endometriotic tissue is inflammation, which is mediated by the overproduction of prostaglandins, metalloproteinases, cytokines, and chemokines. Increased levels of acute inflammatory cytokines such as interleukin-1\(\beta\), interleukin-6, and TNF (tumor necrosis factor) are detected in the peritoneal fluid of women with endometriosis, and probably enhance the adhesion of shed endometrial-tissue fragments onto peritoneal surfaces.\textsuperscript{37–39} A nonhormonal alternative in endometriosis treatment could be modulating inflammation by means of TNF-\(\alpha\) blockers as currently used in other inflammatory diseases such as Crohn’s disease or rheumatoid arthritis.

A small RCT has been published using infliximab, a monoclonal anti-TNF-\(\alpha\) antibody.\textsuperscript{40} Twenty-one patients with severe pain and a rectovaginal nodule were randomized to receive infliximab or placebo prior to surgery, but no differences were found in pain scores among both groups. Three adverse events were reported in the infliximab group: one case of acute tonsillitis, one case of mild infusion reaction, and one case of acute leukemia.

There is not enough evidence to recommend the use of anti-TNF-\(\alpha\) drugs for the treatment of pain associated to endometriosis.

More number of blind randomized controlled trials should be developed in order to define the role of infliximab in the treatment of pain associated to endometriosis, either before or after surgery, and compare it with other medical treatments and other anti-TNF-\(\alpha\) drugs.\textsuperscript{41}

Antiangiogenic factors

Endometriosis is classified as an angiogenic disease. The retrograde menstruation theory\textsuperscript{42} explains pathogenesis of endometriosis due to retrograde menstruation of endometrial tissue, rich in angiogenic growth factors, which implants in the peritoneum. The endometrium from patients with endometriosis reveals a higher angiogenic activity than the endometrium from healthy women, the same as is found in endometriotic lesions and peritoneal fluid from women with endometriosis.\textsuperscript{43–45} Several studies concentrate on antiangiogenic compounds as a promising therapy for endometriosis.\textsuperscript{46}

Growth factor inhibitors

One of the most studied angiogenic factors is the vascular endothelial growth factor (VEGF). The development of anti-VEGF antibody has proved in vitro efficacy in preventing the establishment of endometriotic lesions.\textsuperscript{47–49} Bevacizumab has demonstrated in vitro activity against endometriotic lesions,\textsuperscript{50} but clinical application appears to be limited because of its severe side effects, which include hypertension, proteinuria, hemorrhage and thrombosis, and gastrointestinal perforation.\textsuperscript{51}

Another antiangiogenic factor, 2-methoxyestradiol, tested in studies for cancer, suppresses lesion growth with minimal toxicity.\textsuperscript{52,53} Pharmacokinetic problems due to its extensive first-pass metabolism should be resolved before new clinical trials are conducted.

The future in antiangiogenic therapy for endometriosis seems to be factors which blockade different pathways in the angiogenic cascade.

Endogenous angiogenesis inhibitors

Endostatin is an endogenous antiangiogenic factor that inhibits the development of new vessels. Some studies have shown the inhibition of developing endometriotic lesions\textsuperscript{49} without affecting fertility.\textsuperscript{54} Angiostatin, another endogenous inhibitor of angiogenesis, has been used to treat endometriotic lesions in mice but it disrupts normal ovarian function.\textsuperscript{55}
This problem should be solved in order to advance the use of this agent.

**Fumagillin analog**

Fumagillin, an antibiotic produced by *Aspergillus fumigatus*, shows antiangiogenic activity. Some synthetic derivatives have been developed as well. Only caplostatin shows same antiangiogenic activity in endometriosis lesions but without toxic effects on the female reproductive system and neurotoxicity; hence, it can be candidate for future research in antiangiogenic therapy for endometriosis.

**Statins**

Statins, lipid-lowering drugs, have shown antiangiogenic activity in high doses. Studies with atorvastatin have demonstrated antiangiogenic activity in endometriotic lesions, without side effects on reproductive function. More studies are necessary to ascertain which statin is the most suitable for the antiangiogenic treatment of endometriosis and to achieve antiangiogenic activity at nontoxic doses.

**Cyclooxygenase 2 inhibitors**

Prostaglandin synthesis is mediated by cyclooxygenase 2 (COX-2). Its expression is increased in inflammatory and angiogenic processes. Endometriotic lesions and eutopic endometrium of patients with endometriosis show higher amounts of COX-2 when compared with controls.

Studies in animals have shown that treatment with COX-2 inhibitors prevents the implantation of endometrium to ectopic sites and induces the regression of established endometriotic lesions. A randomized double-blind placebo-controlled study was carried out in 28 women using 25 mg of rofecoxib a day during 6 months. The results showed more effective control of pain in the rofecoxib group than in the placebo group, with no significant side effects.

The results of in vitro studies and this clinical trial presented the COX-2 inhibitors as the ideal option for the treatment of pain associated to endometriosis. However, rofecoxib and valdecoxib have been removed from the market because of severe cardiovascular effects in long-term users.

A study in mice compared the response in endometriotic lesions to celecoxib, anastrozole, or their combination. Celecoxib was the only treatment that significantly reduced the number of lesions established per mouse, lesion size, and vascularized area. In addition, cell proliferation was significantly diminished and apoptosis was significantly enhanced by both individual treatments. When the therapies were combined, their effects were reversed. These results confirm that celecoxib and anastrozole separately decrease endometriotic growth, but when combined they might have antagonizing effects.

There is currently not enough evidence to recommend the use of COX-2 inhibitors for the relief of pain in women with endometriosis, as it is not under clinical trials and for short-term treatment of severe forms of the disease.

**Immunomodulators: pentoxifylline**

Changes in the immune system play an essential role in the pathogenesis of endometriosis. For that reason, immunomodulatory agents, such as pentoxifylline, have been suggested for the treatment of endometriosis. Pentoxifylline has shown antiangiogenic effects in the development of endometriotic lesions in rats, is well tolerated, and does not inhibit ovulation.

Some clinical trials have been published comparing the use of pentoxifylline with placebo after conservative surgery, but there was no evidence of an increase in clinical pregnancy or improvement in pain scores. Adverse events were not reported. A recent Cochrane review concluded that there is little evidence to support using pentoxifylline as a treatment for subfertility in women with endometriosis at this time.

**Conclusion**

Hormonal treatments currently available are effective in the relief of pain associated to endometriosis. Treatments approved and recommended for this purpose include hormonal contraceptives (oral, transdermal, or vaginal administration), progestogens (medroxyprogesterone acetate oral or depot, dienogest, cyproterone acetate, norethindrone acetate, danazol, levonorgestrel intrauterine device) and anti-progestogens (gestrinone), and GnRH agonists.

Among new hormonal drugs, the only ones approved for use in the treatment of pain associated to endometriosis are aromatase inhibitors. They seem to be effective in the relief of pain, and their use is recommended for hormonal treatment in women who do not respond to other treatments.

GnRH antagonists are still under study, with currently active Phase III RCT. They are expected to be as effective as GnRH agonists, but with easier administration.

More number of randomized trials should be developed in order to confirm SPRMs’ efficacy and long-term safety.

There is a need to find effective treatments that do not block ovarian function. New nonhormonal drugs are still...
experimental. For this purpose, antiangiogenic factors could be important components of endometriosis therapy in the future. Upcoming researches and controlled clinical trials should focus on these drugs, in order to establish if they are really effective in relieving pain without affecting fertility.

Disclosure

The authors report no conflicts of interest in this work.

References


